EGFR and neoplasm: Many tumours with intrinsic resistance to erlotinib/gefitinib were found to have wild-type EGFR and/or mutant KRAS. At present, no FDA-approved inhibitor drugs have been shown to be successful in overcoming T790M-mediated resistance clinically.